title: CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells.
abstract: The CD94/NKG2-A complex is the inhibitory receptor for the nonclassical MHC class I molecule HLA-E on human NK cells. Here we studied the molecular mechanisms underlying the inhibitory activity of CD94/NKG2-A on NK cell functions by analyzing its interference on CD16-initiated signaling pathways involved in the control of cytolytic activity. Both tyrosine phosphorylation and activation of Syk kinase together with tyrosine phosphorylation of CD16 receptor zeta subunit are markedly inhibited by the coengagement of CD94/NKG2-A complex. As a downstream consequence, CD94/NKG2-A cross-linking impairs the CD16-induced activation of extracellular regulated kinases (ERKs), a pathway involved in NK cytotoxic function. The block of ERK activation is exerted at an early, PTK-dependent stage in the events leading to p21ras activation, as the CD16-induced tyrosine phosphorylation of Shc adaptor protein and the formation of Shc/Grb-2 complex are abrogated by CD94/NKG2-A simultaneous engagement. Our observations indicate that CD94/NKG2-A inhibits the CD16-triggered activation of two signaling pathways involved in the cytotoxic activity of NK cells. They thus provide molecular evidence to explain the inhibitory function of CD94/NKG2-A receptor on NK effector functions.
authors.affiliation: Department of Experimental Medicine, Istituto Pasteur-Fondazione Cenci Bolognetti, University La Sapienza, Rome, Italy. fmainiero@axrmauniromal.it
authors.forename: G
authors.initials: G
authors.lastname: Palmieri
authors.forename: V
authors.initials: V
authors.lastname: Tullio
authors.forename: A
authors.initials: A
authors.lastname: Zingoni
authors.forename: M
authors.initials: M
authors.lastname: Piccoli
authors.forename: L
authors.initials: L
authors.lastname: Frati
authors.forename: M
authors.initials: M
authors.lastname: Lopez-Botet
authors.forename: A
authors.initials: A
authors.lastname: Santoni
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D004789:Enzyme Activation / Q000276:immunology; D004792:Enzyme Precursors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D007694:Killer Cells, Natural / Q000201:enzymology* / Q000276:immunology; D037181:Lectins, C-Type; D046911:Macromolecular Substances; D012515:Mast-Cell Sarcoma; D008562:Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D051920:NK Cell Lectin-Like Receptor Subfamily D; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017452:Receptors, IgG / Q000037:antagonists & inhibitors / Q000502:physiology*; D000072377:Syk Kinase; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000037:antagonists & inhibitors / Q000378:metabolism; D018631:ras Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D004792:Enzyme Precursors; D047908:Intracellular Signaling Peptides and Proteins; C497869:KLRD1 protein, human; C497870:Klrd1 protein, mouse; D037181:Lectins, C-Type; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins; D051920:NK Cell Lectin-Like Receptor Subfamily D; D017452:Receptors, IgG; D014443:Tyrosine; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase; C000606897:Syk protein, mouse; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D018631:ras Proteins